← Back to Clinical Trials
Recruiting NCT07082608

NCT07082608 Effect of Weight Loss From ESG Plus Lifestyle Changes vs. Lifestyle Changes Alone in Sleep Apnea Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07082608
Status Recruiting
Phase
Sponsor Asian Institute of Gastroenterology, India
Condition OSA - Obstructive Sleep Apnea
Study Type INTERVENTIONAL
Enrollment 74 participants
Start Date 2025-08-19
Primary Completion 2029-05-19

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Endoscopic Sleeve GastropathyLifestyle Modification alone

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 74 participants in total. It began in 2025-08-19 with a primary completion date of 2029-05-19.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Study Overview: Obesity and Obstructive Sleep Apnea (OSA) are strongly linked. This study aims to understand whether a procedure called Endoscopic Sleeve Gastroplasty (ESG), along with lifestyle changes like healthy eating and regular exercise, can help improve symptoms of OSA in people with obesity. What is Obstructive Sleep Apnea (OSA)? OSA is a condition where your breathing repeatedly stops and starts during sleep. This happens when the airway becomes blocked-often due to extra fat around the neck and throat in people with obesity. These breathing interruptions can lead to poor sleep quality, daytime tiredness, mood issues, and long-term health risks like high blood pressure and heart problems. Why Does Weight Matter? Obesity is a major cause of OSA. Being overweight can cause: Narrowing of the airway More inflammation in the body Hormonal changes Difficulty breathing properly during sleep Losing weight can reduce these problems, ease OSA symptoms, and help improve sleep. Even a moderate amount of weight loss can make a big difference. How Can People Lose Weight? Many people try to lose weight through: Diet changes Exercise Behavioural changes like mindful eating These methods can help, but some people find it hard to lose enough weight or keep it off. That's where medical procedures like ESG can help. What is ESG (Endoscopic Sleeve Gastroplasty)? ESG is a non-surgical, minimally invasive weight-loss procedure. It works by reducing the size of your stomach using stitches (done through a tube inserted through your mouth-no cuts or incisions on the body). A smaller stomach means you feel full sooner and eat less. Benefits of ESG: Helps you lose weight (up to 20% of total body weight) Lower risk of complications than traditional surgery Short recovery time No hospital stay in most cases What Does the Research Say So Far? Some early studies have shown that ESG can help people lose a significant amount of weight and may also improve conditions related to obesity, such as OSA. One study followed 99 people for a year after ESG. About 30% had OSA at the start. After the procedure, many reported improvement in their OSA symptoms. Another study compared ESG with a more invasive surgery (laparoscopic sleeve gastrectomy or LSG). While LSG led to more weight loss, both groups showed similar improvements in OSA symptoms. This shows that ESG may be a good option for improving OSA, but more research is needed to fully understand its benefits. Why Is This Study Important? With obesity and OSA becoming more common, it is important to find effective and safe treatments. This study will help us learn: How much ESG can improve sleep and breathing in people with OSA Whether combining ESG with lifestyle changes is better than lifestyle changes alone How ESG impacts other health problems linked to obesity What We Hope to Learn: We believe that weight loss from ESG will: Reduce the severity of OSA Improve sleep quality Improve overall health The results of this study could help guide future treatment options for people with obesity and sleep apnea.

Eligibility Criteria

Inclusion Criteria: 1. Age \> 18years. 2. Obesity defined by ethnic specific BMI cut-offs through \< 40 kg/m². 3. Diagnosed with moderate to severe OSA (Apnea-Hypopnea Index \[AHI\] ≥15). 4. Stable weight (\< 5 kg change) within 3 months prior to screening 5. Failure or inadequate weight loss with conservative methods: 1. lifestyle modification. and/or 2. anti-obesity medications 6. No planned additional weight loss treatments (i.e. OTC supplements, pharmacotherapy or bariatric surgery) during the first 12-months following study treatment 7. Willingness to comply with the study protocol, including in office follow-up visits and lifestyle modifications. 8. Able to sign, understand, and sign a written Informed Consent Form to participate in the study. Exclusion Criteria: 1. Any previous or planned surgery for sleep apnea or major ear, nose, or throat surgery 2. Significant craniofacial abnormalities that may affect breathing 3. Diagnosis of central or mixed sleep apnea, or diagnosis of Cheyne-Stokes Respiration Obesity related 4. History of disorder, other than OSA, associated with insomnia or excessive daytime sleepiness 5. Obesity induced by other endocrinologic disorders, or monogenetic or syndromic forms of obesity 6. Active device treatment of OSA other than continuous positive airway pressure therapy 7. Requires the use of supplemental oxygen 8. Previous bariatric surgery or any other gastrointestinal surgery where primary ESG will not be feasible. 9. Active inflammatory bowel disease. 10. Current or planned pregnancy or breastfeeding while participating in the study. 11. Severe cardiopulmonary conditions contraindicating endoscopy. 12. Uncontrolled psychiatric disorders. 13. Eating disorder that will impact the ability of the subject to follow the lifestyle modification program 14. History of substance abuse. 15. Use of any over-the-counter or prescription medications that could affect the evaluation of excessive sleepiness 16. Type 2 diabetics that has had a change within 3 months of the screening visit or planned change in medication for blood sugar management that has thee potential to impact weight loss (i.e. GLP-1 medications)

Contact & Investigator

Central Contact

Rakesh Kalapala, MD, DNB

✉ drrakeshkalapala@aighospitals.com

📞 040 42444 4222

Principal Investigator

Rakesh Kalapala, MD, DNB

PRINCIPAL INVESTIGATOR

Asian Institute of Gastroeterology

Frequently Asked Questions

Who can join the NCT07082608 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying OSA - Obstructive Sleep Apnea. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07082608 currently recruiting?

Yes, NCT07082608 is actively recruiting participants. Contact the research team at drrakeshkalapala@aighospitals.com for enrollment information.

Where is the NCT07082608 trial being conducted?

This trial is being conducted at Hyderabad, India.

Who is sponsoring the NCT07082608 clinical trial?

NCT07082608 is sponsored by Asian Institute of Gastroenterology, India. The principal investigator is Rakesh Kalapala, MD, DNB at Asian Institute of Gastroeterology. The trial plans to enroll 74 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology